工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy.
Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
TIL(肿瘤浸润淋巴细胞)疗法为晚期、治疗耐药性恶性肿瘤患者带来了新希望。lifileucel是一项开创性的癌症免疫治疗进展。这种先进细胞疗法利用TIL天然靶向肿瘤的能力,革新了免疫系统对抗癌症的方式。作为创新药物,lifileucel正受到肿瘤学界关注。临床试验显示疗效显著,可帮助对其他疗法无应答的患者维持应答并延长生存。本综述全面概述lifileucel的现代理解,包括作用机制、临床结果、挑战及其拓展至更广泛实体瘤的潜在适用性。lifileucel理念开启了个体化癌症治疗的新阶段。本综述前瞻性探讨lifileucel及TIL疗法成为癌症治疗基石的潜在进展与机遇。
Lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, provides renewed hope for individuals with advanced, treatment-resistant malignancies. This is a groundbreaking advancement in cancer immunotherapy. Revolutionizing the way the immune system fights cancer, this state-of-the-art cellular therapy takes advantage of TILs' innate capacity to target tumors. Lifileucel is an innovative medicine that is garnering attention in oncology. It has shown remarkable efficacy in clinical trials, assisting individuals unresponsive to other therapy in sustaining their responses and enhancing their survival rates.
This paper provides a comprehensive overview of contemporary perspectives on Lifileucel, including its mechanism of action, clinical results, challenges and potential applicability to a broader spectrum of solid tumors. The Lifileucel concept has initiated a new epoch in personalized cancer therapy. This review offers a forward-looking perspective on the potential advancements and opportunities for establishing Lifileucel and TIL-based therapies as a cornerstone in cancer therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。